Dyadic Highlights C1 Platform Adoption for Ebola Preparedness and Commercial Expansion

On June 15, 2026, Dyadic International, Inc. (Nasdaq: DYAI) issued a press release highlighting the accelerated interest and commercial adoption of its proprietary C1 and Dapibus protein production platforms. The company is currently engaged in three distinct tracks related to Ebola preparedness: a collaboration with Scripps Research for antigen design, research proposals submitted to CEPI for vaccine manufacturing, and an initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub for monoclonal antibodies. Dyadic's C1 platform has demonstrated the ability to progress from viral gene sequence to purified recombinant antigen or antibody in approximately 15 days, a speed critical for infectious disease outbreaks. Beyond pandemic preparedness, the company reported commercial milestones including the launch of recombinant human albumin with Proliant Health & Biologicals and bovine chymosin with Inzymes. The company estimates its addressable market opportunities exceed $25 billion across life sciences, food, nutrition, and industrial applications. Dyadic's DYAI-100 clinical study previously supported the safety of C1-produced antigens.